amitriptyline has been researched along with Diabetes Mellitus, Adult-Onset in 4 studies
Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.
amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sixty-seven participants with painful diabetic neuropathy were randomized to receive either 2 mg naltrexone or 10 mg amitriptyline daily following a 2-week run-in period." | 9.41 | Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. ( Bansal, D; Bhansali, AK; Chakrabarti, A; Dutta, P; Hota, D; Srinivasan, A, 2021) |
| "Eighty inpatients with an episode of major depressive disorder (DSM-IV criteria) were treated in a double-blind, randomized protocol with either amitriptyline or paroxetine over a period of 5 weeks." | 6.72 | Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. ( Deuschle, M; Gilles, M; Heuser, I; Lederbogen, F; Weber-Hamann, B, 2006) |
| "Sixty-seven participants with painful diabetic neuropathy were randomized to receive either 2 mg naltrexone or 10 mg amitriptyline daily following a 2-week run-in period." | 5.41 | Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial. ( Bansal, D; Bhansali, AK; Chakrabarti, A; Dutta, P; Hota, D; Srinivasan, A, 2021) |
| "Eighty inpatients with an episode of major depressive disorder (DSM-IV criteria) were treated in a double-blind, randomized protocol with either amitriptyline or paroxetine over a period of 5 weeks." | 2.72 | Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. ( Deuschle, M; Gilles, M; Heuser, I; Lederbogen, F; Weber-Hamann, B, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gabriel-Alayode, OE | 1 |
| Omotola, SL | 1 |
| Elegbede, OT | 1 |
| Ajetunmobi, OA | 1 |
| Agboola, SM | 1 |
| Jimoh, AK | 1 |
| Elegbede, AO | 1 |
| Srinivasan, A | 1 |
| Dutta, P | 1 |
| Bansal, D | 1 |
| Chakrabarti, A | 1 |
| Bhansali, AK | 1 |
| Hota, D | 1 |
| Sokov, EL | 1 |
| Arsiukhin, NA | 1 |
| Kornilova, LE | 1 |
| Nozdriukhina, NV | 1 |
| Weber-Hamann, B | 1 |
| Gilles, M | 1 |
| Lederbogen, F | 1 |
| Heuser, I | 1 |
| Deuschle, M | 1 |
3 trials available for amitriptyline and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: A randomized, double-blind, active-control, crossover clinical trial.
Topics: Amitriptyline; Analgesics, Non-Narcotic; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Neu | 2021 |
[The complex treatment of the pain syndrome in diabetic distal polyneuropathy using intraosteal blockades].
Topics: Aged; Amitriptyline; Analgesia; Analgesics, Non-Narcotic; Bone and Bones; Combined Modality Therapy; | 2012 |
Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Di | 2006 |
1 other study available for amitriptyline and Diabetes Mellitus, Adult-Onset
| Article | Year |
|---|---|
Effect of an Antidepressant on Medication Adherence among Type 2 Diabetic Patients with Depression Accessing Care in GOPC of FETHI.
Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Amitriptyline; Antidepressive Agents; Depression; | 2023 |